drugset / Trial / NCT07106892
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
Timeline
- Start
- 2025-09-15
- Primary completion
- 2026-12-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 3 mg/kg | Intravenous |